The connection between the toxicity of anthracyclines and their ability to modulate the P-glycoprotein-mediated transport in A549, HepG2, and MCF-7 cells

The Scientific World Journal

Volumn 2014, Issue , 2014, Pages

  Rogalska, Aneta ^a   Szwed, Marzena ^a   Rychlik, Błazej ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC ANTIBIOTIC; MULTIDRUG RESISTANCE PROTEIN;

ARTICLE; CELL MEMBRANE; DRUG EFFECT; HEPG2 CELL LINE; HUMAN; MCF 7 CELL LINE; METABOLISM; PHYSIOLOGY; PROTEIN TRANSPORT;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CELL MEMBRANE; HEP G2 CELLS; HUMANS; MCF-7 CELLS; P-GLYCOPROTEIN; PROTEIN TRANSPORT;

EID: 84893875683     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2014/819548     Document Type: Article

References (41)

1. Chung W. B., Yi J. E., Jin J. Y., Choi Y. S., Park C. S., Park W. C., Song B. J., Youn H. J., Early cardiac function monitoring for detection of subclinical Doxorubicin cardiotoxicity in young adult patients with breast cancer. Journal of Breast Cancer 2013 16 2 178 183 10.4048/jbc.2013.16.2.178
2. Dudka J., The role of reactive oxygen and nitrogen species in calcium and iron homeostasis dysregulation in anthracycline cardiotoxicity. Postepy Higieny i Medycyny Doswiadczalnej 2006 60 241 247 2-s2.0-33846105088
3. Lo Y.-L., Liu Y., Tsai J.-C., Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo. Biomedicine & Pharmacotherapy 2013 67 4 261 267 10.1016/j.biopha.2012.12.002
4. Kubo T., Takigawa N., Osawa M., Harada D., Ninomiya T., Ochi N., Ichihara E., Yamane H., Tanimoto M., Kiura K., Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy. Cancer Science 2013 104 1 78 84 10.1111/cas.12045
5. Gruber B. M., Anuszewska E. L., Bubko I., Goździk A., Fokt I., Priebe W., Effect of structural modification at the 4, 3′ and 2′ positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells. Archivum Immunologiae et Therapiae Experimentalis 2007 55 3 193 198 2-s2.0-34250786135 10.1007/s00005-007-0018-6 (Pubitemid 46953939)
6. Sharom F. J., ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008 9 1 105 127 2-s2.0-40949121607 10.2217/14622416.9.1.105 (Pubitemid 351560534)
7. Gottesman M. M., Ling V., The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Letters 2006 580 4 998 1009 2-s2.0-31844444140 10.1016/j.febslet.2005.12.060 (Pubitemid 43185280)
8. Sandor V., Fojo T., Bates S. E., Future perspectives for the development of P-glycoprotein modulators. Drug Resistance Updates 1998 1 3 190 200 2-s2.0-0001223675 10.1016/S1368-7646(98)80039-3
9. Hajji N., Mateos S., Pastor N., Domínguez I., Cortés F., Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor. Mutation Research 2005 583 1 26 35 2-s2.0-18144375218 10.1016/j.mrgentox.2005.01.012 (Pubitemid 40615200)
10. Zhu H. H., Jiang H., Jiang B., Lu J., Jiang Q., Bao L., Zhang X. H., Qin Y. Z., Huang X. J., Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy. Leukemia & lymphoma 2013 54 11 2452 2457 10.3109/10428194. 2013.776679
11. Zhang X., Li Y., Zhang Y., Chen X., Zhang C., Gao L., Kong P., Liu Y., Wen Q., Zeng Y., Wang Q., Su Y., Wang C., Wang S., Yuan Z., Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: a multicenter, randomized control trial in southwest China. Leukemia & lymphoma 2013 37 6 657 664 10.1016/j.leukres.2013.03.005
12. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L., Anthracyclines: molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity. Pharmacological Reviews 2004 56 2 185 229 2-s2.0-2642566088 10.1124/pr.56.2.6 (Pubitemid 38720829)
13. Li H.-Y., Yue H., Wei X.-D., Zhu X.-H., Zhang Y.-L., Zhang L.-N., Liu Y.-Y., Wang P., Fang B.-J., Li Y.-F., Song Y.-P., The efficacy of high-dose cytarabine for patients with t(8;21) AML and with normal karyotype AML. Zhonghua Xue Ye Xue Za Zhi 2008 29 2 110 112 2-s2.0-77950492307
14. Baldissera V. D., de Mattos A. A., Coral G. P., de Araujo F. B., Marroni C. A., de Mello Brandao A. B., Ott Fontes P. R., Schmidt Cerski C. T., Hartmann A. A., Kretzmann Filho N. A., Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma. Annals of Hepatology 2012 11 6 899 906
15. Lehne G., De Angelis P., Clausen O. P. F., Rugstad H. E., Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines. British Journal of Cancer 1996 74 11 1719 1729 2-s2.0-0029801099 (Pubitemid 26401890)
16. Coley H. M., Twentyman P. R., Workman P., Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A. Biochemical Pharmacology 1989 38 24 4467 4475 2-s2.0-0024819898 10.1016/0006-2952(89)90658-8 (Pubitemid 20027547)
17. Schwab D., Fischer H., Tabatabaei A., Poli S., Huwyler J., Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. Journal of Medicinal Chemistry 2003 46 9 1716 1725 2-s2.0-0037464458 10.1021/jm021012t (Pubitemid 36444224)
18. Chaoui D., Faussat A.-M., Majdak P., Tang R., Perrot J.-Y., Pasco S., Klein C., Marie J.-P., Legrand O., JC-1, a sensitive probe for a simultaneous detection of P-glycoprotein activity and apoptosis in leukemic cells. Cytometry: Part B 2006 70 3 189 196 2-s2.0-33646470009 10.1002/cyto.b.20100
19. Zhou C., Shen P., Cheng Y., Quantitative study of the drug efflux kinetics from sensitive and MDR human breast cancer cells. Biochimica et Biophysica Acta 2007 1770 7 1011 1020 2-s2.0-34247598330 10.1016/j.bbagen.2007. 02.011 (Pubitemid 46678607)
20. Galluzzi L., Zamzami N., Rouge T. D. L. M., Lemaire C., Brenner C., Kroemer G., Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis 2007 12 5 803 813 2-s2.0-34247549680 10.1007/s10495-007-0720-1 (Pubitemid 46653289)
21. Rogalska A., Szwed M., Jóźwiak Z., Aclarubicin-induced apoptosis and necrosis in cells derived from human solid tumours. Mutation Research 2010 700 1-2 1 10 2-s2.0-77953912036 10.1016/j.mrgentox.2010.04.013
22. Rogalska A., Koceva-Chyła A., Jóźwiak Z., Aclarubicin-induced ROS generation and collapse of mitochondrial membrane potential in human cancer cell lines. Chemico-Biological Interactions 2008 176 1 58 70 2-s2.0-52949118817 10.1016/j.cbi.2008.07.002
23. Barraud L., Merle P., Soma E., Lefrançois L., Guerret S., Chevallier M., Dubernet C., Couvreur P., Trépo C., Vitvitski L., Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. Journal of Hepatology 2005 42 5 736 743 2-s2.0-20144389123 10.1016/j.jhep.2004.12.035
24. Li L., Jiang A. C., Dong P., Wan Y., Yu Z. W., The characteristics of Hep-2 cell with multiple drug resistance induced by Taxol. Otolaryngology 2007 137 4 659 664 2-s2.0-34548822403 10.1016/j.otohns.2007.04.026 (Pubitemid 47445893)
25. 1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer. Molecular Cancer Therapeutics 2006 5 7 1807 1816 2-s2.0-33748291765 10.1158/1535-7163.MCT-05-0402 (Pubitemid 44323249)
26. Lo S., Tolner B., Taanman J.-W., Cooper J. M., Gu M., Hartley J. A., Schapira A. H. V., Hochhauser D., Assessment of the significance of mitochondrial DNA damage by chemotherapeutic agents. International Journal of Oncology 2005 27 2 337 344 2-s2.0-33644670758
27. 18FDG. European Journal of Pharmaceutical Sciences 2010 41 5 665 669 2-s2.0-78349307009 10.1016/j.ejps.2010.09.009
28. Scheffer G. L., Pijnenborg A. C. L. M., Smit E. F., Müller M., Postma D. S., Timens W., van der Valk P., de Vries E. G. E., Scheper R. J., Multidrug resistance related molecules in human and murine lung. Journal of Clinical Pathology 2002 55 5 332 339 2-s2.0-0036260972 (Pubitemid 34494170)
29. Hira A., Watanabe H., Maeda Y., Yokoo K., Sanematsu E., Fujii J., Sasaki J.-I., Hamada A., Saito H., Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells. Biochemical Pharmacology 2008 75 4 973 980 2-s2.0-38649143669 10.1016/j.bcp.2007.10.023 (Pubitemid 351174119)
30. Volm M., Mattern J., Samsel B., Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170, and glutathione S-transferase-pi in human lung tumors. Cancer 1992 70 4 764 769 10.1002/1097-0142(19920815)70:4<764::AID-CNCR2820700408>3.0.CO;2-M
31. Hamilton K. O., Topp E., Makagiansar I., Siahaan T., Yazdanian M., Audus K. L., Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. Journal of Pharmacology and Experimental Therapeutics 2001 298 3 1199 1205 2-s2.0-0034892459 (Pubitemid 32761940)
32. Yoh K., Ishii G., Yokose T., Minegishi Y., Tsuta K., Goto K., Nishiwaki Y., Kodama T., Suga M., Ochiai A., Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clinical Cancer Research 2004 10 5 1691 1697 2-s2.0-12144287061 10.1158/1078-0432.CCR-0937-3 (Pubitemid 38435560)
33. Merk J., Rolff J., Dorn C., Leschber G., Fichtner I., Chemoresistance in non-small-cell lung cancer: can multidrug resistance markers predict the response of xenograft lung cancer models to chemotherapy? European Journal of Cardio-Thoracic Surgery 2011 40 1 e29 e33 2-s2.0-79958001559 10.1016/j.ejcts.2011.02.010
34. Okuyama T., Maehara Y., Endo K., Baba H., Adachi Y., Kuwano M., Sugimachi K., Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin. Cancer 1994 74 4 1230 1236 10.1002/1097- 0142(19940815)74:4<1230::AID-CNCR2820740409>3.0.CO;2-0 (Pubitemid 24301773)
35. Nakamura S., Takeichi T., Yamanaka C., Shichijo K., Takahashi K., Hiasa Y., Matsushita T., Horiuchi N., Tamaki Y., Kimura S., Fujimoto H., Masuda K., Shinomiya S., Multiple hepatocellular carcinomas developed 15 months after commencement of chemotherapy for elderly acute myelogenous leukemia. Rinshō ketsueki 2009 50 11 1616 1620 2-s2.0-77449143393 10.11406/rinketsu.50.1616
36. Akimoto M., Yoshikawa M., Ebara M., Sato T., Fukuda H., Kondo F., Saisho H., Relationship between therapeutic efficacy of arterial infusion chemotheraphy and expression of P-glycoprotein and p53 protein in advanced hepatocellular carcinoma. World Journal of Gastroenterology 2006 12 6 868 873 2-s2.0-33645072203 10.3748/wjg.v12.i6.868
37. Sun Z., Zhao Z., Li G., Dong S., Huang Z., Ye L., Liang H., Qu J., Ai X., Zhang W., Chen X., Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: in vivo and clinical studies. Tumori 2010 96 1 90 96 2-s2.0-77950815774 10.1700/479.5657
38. Burger H., Foekens J. A., Look M. P., Gelder M. E. M.-V., Klijn J. G. M., Wiemer E. A. C., Stoter G., Nooter K., RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clinical Cancer Research 2003 9 2 827 836 2-s2.0-0037314795 (Pubitemid 36182621)
39. Calcagno A. M., Fostel J. M., To K. K. W., Salcido C. D., Martin S. E., Chewning K. J., Wu C.-P., Varticovski L., Bates S. E., Caplen N. J., Ambudkar S. V., Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. British Journal of Cancer 2008 98 9 1515 1524 2-s2.0-43249107455 10.1038/sj.bjc.6604334 (Pubitemid 351652329)
40. Cripe L. D., Uno H., Paietta E. M., Litzow M. R., Ketterling R. P., Bennett J. M., Rowe J. M., Lazarus H. M., Luger S., Tallman M. S., Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 2010 116 20 4077 4085 2-s2.0-78549238612 10.1182/blood-2010-04-277269
41. Xu H.-B., Li L., Fu J., Mao X.-P., Xu L.-Z., Reversion of multidrug resistance in a chemoresistant human breast cancer cell line by beta-elemene. Pharmacology 2012 89 303 312 10.1159/000337178